Invitrogen Acquisition Spree to Continue Unabated as it Eyes Molecular Dx Growth | GenomeWeb

Invitrogen expects to continue its aggressive acquisition strategy through the remainder of the year, but it is possible after a string of relatively small purchases that the firm may be ready to add a "transforming" piece to its business, CEO Greg Lucier suggested during a webcast last week.

Lucier was one of several members of Invitrogen's management to address attendees of the company's 2005 investor meeting at its headquarters in Carlsbad, Calif.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.